Search
Gemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigationalGemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias. … [A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure, 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acidBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnIt has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. … It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINE, 1-PYRROLIDENEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-Alimemazine
go.drugbank.com/drugs/DB01246ApprovedVet approvedWithdrawnA phenothiazine derivative that is used as an antipruritic.
Categories: Heterocyclic Compounds, 3-RingIsocarboxazid
go.drugbank.com/drugs/DB01247ApprovedIsocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. … [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Heterocyclic Compounds, 1-RingOlsalazine
go.drugbank.com/drugs/DB01250ApprovedOlsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). … [A257063] Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151]
Categories: Non COX-2 selective NSAIDSMitiglinide
go.drugbank.com/drugs/DB01252InvestigationalMitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
Categories: Heterocyclic Compounds, 2-RingDasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigationalBCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases. … [A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamideLapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinaminePaliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalPaliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 9-hydroxyrisperidoneSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalSunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. … These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: DOSTINIB® 25MG, DOSTINIB® 50MG